tetano
Editor, Senior Moderator
Hum Vaccin Immunother
. 2025 Dec;21(1):2525603.
doi: 10.1080/21645515.2025.2525603. Epub 2025 Jul 11. The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024
Yihao Li[SUP] 1 [/SUP], Huilin Xia[SUP] 1 [/SUP], Hong Zhang[SUP] 1 [/SUP], Yuan Lu[SUP] 1 [/SUP], Hang Zhou[SUP] 1 [/SUP], Rongbin Yu[SUP] 1 [/SUP], Peng Huang[SUP] 1 [/SUP]
Affiliations
This post-marketing safety study evaluated the co-administration of recombinant zoster vaccine (RZV, Shingrix) and influenza vaccines (HD-IIV/aIIV/RIV) in adults aged ≥ 65 years using U.S. VAERS data (2018-2024). Among 791 adverse event (AE) reports analyzed via empirical Bayesian data mining and clinical review, 55 (6.9%) were serious, with non-serious AEs dominated by injection site reactions (65%), pyrexia (15.2%), and chills (13.4%). Serious AEs included asthenia (8.1%), pyrexia (8.1%), and Guillain-Barré syndrome (GBS, 6.4%); clinical review confirmed 7 Brighton-criteria GBS cases and one Bell's palsy. Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/RZV alone), showing no elevated risks. These findings support co-administration safety in older adults, advocating for community pharmacy-based delivery to optimize coverage. Limitations include VAERS' passive surveillance nature (underreporting, lack of denominator data), necessitating cautious interpretation and ongoing monitoring.
Keywords: Vaccine safety; adverse event; co-administration; influenza vaccine; recombinant zoster vaccine; surveillance.
. 2025 Dec;21(1):2525603.
doi: 10.1080/21645515.2025.2525603. Epub 2025 Jul 11. The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018-2024
Yihao Li[SUP] 1 [/SUP], Huilin Xia[SUP] 1 [/SUP], Hong Zhang[SUP] 1 [/SUP], Yuan Lu[SUP] 1 [/SUP], Hang Zhou[SUP] 1 [/SUP], Rongbin Yu[SUP] 1 [/SUP], Peng Huang[SUP] 1 [/SUP]
Affiliations
- PMID: 40641250
- DOI: 10.1080/21645515.2025.2525603
This post-marketing safety study evaluated the co-administration of recombinant zoster vaccine (RZV, Shingrix) and influenza vaccines (HD-IIV/aIIV/RIV) in adults aged ≥ 65 years using U.S. VAERS data (2018-2024). Among 791 adverse event (AE) reports analyzed via empirical Bayesian data mining and clinical review, 55 (6.9%) were serious, with non-serious AEs dominated by injection site reactions (65%), pyrexia (15.2%), and chills (13.4%). Serious AEs included asthenia (8.1%), pyrexia (8.1%), and Guillain-Barré syndrome (GBS, 6.4%); clinical review confirmed 7 Brighton-criteria GBS cases and one Bell's palsy. Data mining detected no new safety signals, and comparative analysis revealed that co-administration safety aligned with clinical trial profiles and monotherapy (influenza/RZV alone), showing no elevated risks. These findings support co-administration safety in older adults, advocating for community pharmacy-based delivery to optimize coverage. Limitations include VAERS' passive surveillance nature (underreporting, lack of denominator data), necessitating cautious interpretation and ongoing monitoring.
Keywords: Vaccine safety; adverse event; co-administration; influenza vaccine; recombinant zoster vaccine; surveillance.